Conference Coverage

Optimizing use of TKIs in chronic leukemia


 

REPORTING FROM LEUKEMIA AND LYMPHOMA 2018

Discontinuing a TKI

Dr. Kantarjian said patients can discontinue TKI therapy if they:

  • Are low- or intermediate-risk by Sokal.
  • Have quantifiable BCR-ABL transcripts.
  • Are in chronic phase.
  • Achieved an optimal response to their first TKI.
  • Have been on TKI therapy for more than 8 years.
  • Achieved a complete molecular response.
  • Have had a molecular response for more than 2-3 years.
  • Are available for monitoring every other month for the first 2 years.

Dr. Kantarjian did not report any conflicts of interest at the meeting. However, he has previously reported relationships with Novartis, Bristol-Myers Squibb, Pfizer, and Ariad Pharmaceuticals.

The Leukemia and Lymphoma meeting is organized by Jonathan Wood & Association, which is owned by the parent company of this news organization.

Next Article: